A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.
Fiche publication
Date publication
juin 2018
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre, Dr HABERSETZER François, Dr MINELLO Anne
Tous les auteurs :
Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R
Lien Pubmed
Résumé
Patients with primary biliary cholangitis who have an inadequate response to therapy with ursodeoxycholic acid are at high risk for disease progression. Fibrates, which are agonists of peroxisome proliferator-activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with this condition.
Mots clés
Adult, Bezafibrate, adverse effects, Bile Acids and Salts, blood, Cholangitis, drug therapy, Double-Blind Method, Female, Humans, Hypolipidemic Agents, adverse effects, Liver Cirrhosis, Biliary, complications, Male, Middle Aged, Placebos, therapeutic use, Treatment Failure, Ursodeoxycholic Acid, therapeutic use
Référence
N. Engl. J. Med.. 2018 06 7;378(23):2171-2181